Table 3.
Association between laboratory markers of hydroxyurea adherence and healthcare utilization.
| All participants (N = 113) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergency room visits (rate/year) |
Hospitalizations (rate/year) |
LOS hospitalizations (days/year) |
||||||||||
| All (rs) | p Value | HU (rs) | p Value | All (rs) | p Value | HU (rs) | p Value | All (rs) | p Value | HU (rs) | p Value | |
| HbF | ||||||||||||
| Most recent | −0.18 | .07 | −0.26 | .01 | −0.21 | .03 | −0.27 | .01 | −0.23 | .02 | −0.27 | .0045 |
| Last 1 year | −0.27 | .02 | −0.30 | .01 | −0.25 | .03 | −0.30 | .01 | −0.26 | .02 | −0.32 | .004 |
| Last 2 year | −0.14 | .36 | −0.01 | .32 | −0.25 | .04 | −0.28 | .02 | −0.27 | .03 | −0.31 | .01 |
| MCV | ||||||||||||
| Most recent | −0.20 | .04 | −0.23 | .01 | −0.18 | .06 | −0.14 | .25 | −0.22 | .02 | −0.14 | .13 |
| Last 1 year | −0.20 | .08 | −0.15 | .17 | −0.19 | .08 | −0.11 | .32 | −0.24 | .03 | −0.12 | .27 |
| Last 2 year | −0.24 | .05 | −0.18 | .07 | −0.31 | .01 | −0.17 | .15 | −0.34 | .004 | −0.19 | .11 |
| ANC | ||||||||||||
| Most recent | 0.23 | .02 | 0.24 | .01 | 0.22 | .02 | 0.21 | .02 | 0.22 | .02 | 0.23 | .02 |
| Last 1 year | 0.25 | .02 | 0.25 | .03 | 0.18 | .11 | 0.17 | .12 | 0.14 | .20 | 0.15 | .27 |
| Last 2 year | 0.14 | .24 | 0.06 | .66 | 0.18 | .13 | 0.15 | .22 | 0.16 | .19 | 0.15 | .23 |
| Participants with HbSS (N = 99) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergency room visits (rate/year) |
Hospitalizations (rate/year) |
LOS hospitalizations (days/year) |
||||||||||
| All (rs) | p Value | HU (rs) | p Value | All (rs) | p Value | HU (rs) | p Value | All (rs) | p Value | HU (rs) | p Value | |
| HbF | ||||||||||||
| Most recent | −0.15 | .14 | −0.20 | .045 | −0.18 | .09 | −0.25 | .015 | −0.18 | .08 | −0.25 | .01 |
| Last 1 year | −0.21 | .07 | −0.21 | .07 | −0.17 | .14 | −0.22 | .07 | −0.17 | .2 | −0.23 | .05 |
| Last 2 year | −0.05 | .56 | −0.02 | .87 | −0.16 | .22 | −0.19 | .15 | −0.17 | .2 | −0.20 | .11 |
| MCV | ||||||||||||
| Most recent | −0.16 | .13 | −0.14 | .16 | −0.16 | .13 | −0.11 | .27 | −0.22 | .03 | −0.12 | .26 |
| Last 1 year | −0.13 | .25 | −0.02 | .88 | −0.12 | .29 | −0.004 | .97 | −0.18 | .11 | −0.01 | .93 |
| Last 2 year | −0.24 | .06 | −0.08 | .54 | −0.27 | .04 | −0.15 | .26 | −0.31 | .01 | −0.16 | .22 |
| ANC | ||||||||||||
| Most recent | 0.21 | .04 | 0.22 | .03 | 0.26 | .01 | 0.22 | .03 | 0.27 | .01 | 0.24 | .02 |
| Last 1 year | 0.24 | .04 | 0.23 | .04 | 0.19 | .11 | 0.16 | .17 | 0.15 | .18 | 0.16 | .19 |
| Last 2 year | 0.16 | .22 | 0.07 | .60 | 0.24 | .06 | 0.17 | .19 | 0.22 | .09 | 0.18 | .16 |
p < 0.05 was statistically significant (highlighted in bold).
rs, Spearman rho correlations; “All” is defined as entire follow up period, including HU therapy; “HU” is defined as being on HU.
ANC: absolute neutrophil count; HbF: foetal haemoglobin; HU: hydroxyurea; LOS: length of stay; MCV: mean corpuscular volume.